The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity

Journal of Neuroscience

Volumn 22, Issue 20, 2002, Pages 9122-9133

  Blum, David ^a   Gall, David ^a   Galas, Marie Christine ^a   D'Alcantara, Pablo ^a   Bantubungi, Kadiombo ^a   Schiffmann, Serge N ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

3 nitropropionic acid; A1 receptor; Adenosine; Cell death; Huntington's disease; Neuroprotection; Striatum

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE AMINE CONGENER; ADENOSINE DERIVATIVE; UNCLASSIFIED DRUG; 3-NITROPROPIONIC ACID; ADENOSINE; ADENOSINE RECEPTOR; DRUG DERIVATIVE; ENKEPHALIN; MESSENGER RNA; NEUROPROTECTIVE AGENT; NEUROTOXIN; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DYSTONIA; EXCITATORY POSTSYNAPTIC POTENTIAL; HINDLIMB; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; NERVE DEGENERATION; NERVE EXCITABILITY; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; STRIATE CORTEX; ANIMAL; ANIMAL BEHAVIOR; BINDING COMPETITION; BIOSYNTHESIS; BODY WEIGHT; BRAIN CORTEX; CHEMICALLY INDUCED DISORDER; CORPUS STRIATUM; DISEASE MODEL; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; IN VITRO STUDY; LEWIS RAT; METABOLISM; MITOCHONDRION; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; REPRODUCIBILITY; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

ADENOSINE; ANIMALS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BODY WEIGHT; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSTONIA; ENKEPHALINS; HINDLIMB; HUNTINGTON DISEASE; MALE; MITOCHONDRIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRO COMPOUNDS; PROPIONIC ACIDS; RATS; RATS, INBRED LEW; RECEPTORS, PURINERGIC P1; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SUCCINATE DEHYDROGENASE; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 0037107346     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.22-20-09122.2002     Document Type: Article

References (77)

1. 2 receptors. Eur J Pharmacol 227:317-324.
2. Aden U, Leverin AL, Hagberg H, Fredholm BB (2001) Adenosine A(1) receptor agonism in the immature rat brain and heart. Eur J Pharmacol 426:185-192.
3. Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF (2001a). Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8:479-491.
4. Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF (2001b) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 50:112-117.
5. Bachoud-Levi AC, Remy P, Nguyen JP, Brugieres P, Lefaucheur JP, Bourdet C, Baudic S, Gaura V, Maison P, Haddad B, Boisse MF, Grandmougin T, Jeny R, Bartolomeo P, Dalla BG, Degos JD, Lisovoski F, Ergis AM, Pailhous E, Cesaro P, Hantraye P, Peschanski M (2000) Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356:1975-1979.
6. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192.
7. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB (1994) Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36:882-888.
8. 1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders. Ann NY Acad Sci 825:23-29.
9. Bizat C, Créminon JM, Hermel F, Condé F, Boyer S, Ouary S, Krajewski JC, Reed P, Hantraye P, Brouillet E (2001) In vivo study of the apoptotic machinery in the preferential neurodegeneration of the striatum due to chronic energy compromise. Soc Neurosci Abstr 31:432.6.
10. Blum D, Gall D, Cuvelier L, Schiffmann SN (2001) Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport 12:1769-1772.
11. Blum D, Galas MC, Gall D, Cuvelier L, Schiffmann SN (2002) Striatal and cortical neurochemical changes induced by a chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol Dis 10:410-426.
12. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad USA 92:7105-7109.
13. Brouillet E, Guyot MC, Mittoux V, Altairac S, Conde F, Palfi S, Hantraye P (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 70:794-805.
14. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59:427-468.
15. Connick JH, Stone TW (1989) Quinolinic acid neurotoxicity: Protection by intracerebral phenylisopropyladenosine (PIA) and potentiation by hypotension. Neurosci Lett 101:191-196.
16. 2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107:455-464.
17. 1 receptors in the striatum: Different interactions with the dopaminergic system. Eur J Neurosci 11:3101-3114.
18. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L, Zoli M, Schiffmann SN (2001) Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 78:183-198.
19. Dautry C, Conde F, Brouillet E, Mittoux V, Beal MF, Bloch G, Hantraye P (1999) Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol Dis 6:259-268.
20. Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, Bloch G, Hantraye P (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20:789-799.
21. De Almeida LP, Zala D, Aebischer P, Deglon N (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 8:433-446.
22. 1 receptor activation. NeuroReport 6:1097-1100.
23. De Mendonca A, Sebastiao AM, Ribeiro JA (2000) Adenosine: Does it have a neuroprotective role after all? Brain Res Brain Res Rev 33:258-274.
24. 1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. Eur J Pharmacol 317:239-245.
25. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
26. Dunwiddie TV, Masino SA (2001) The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31-55.
27. El Massioui N, Ouary S, Cheruel F, Hantraye P, Brouillet E (2001) Perseverative behavior underlying attentional set shifting deficit in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp Neurol 172:172-181.
28. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH (1997) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 386:395-399.
29. 1 receptor-mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro. Brain Res 778:178-185.
30. Fredholm BB, Dunwiddie TV (1988) How does adenosine inhibit transmitter release? Trends Pharmacol Sci 9:130-134.
31. Galas MC, Chasserot-Golaz S, Dirrig-Grosch S, Bader MF (2000) Presence of dynamin-syntaxin complexes associated with secretory granules in adrenal chromaffin cells. J Neurochem 75:1511-1519.
32. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E (1997a) Quantifiable bradykinesia, gait abnormalities and Huntington's diseaselike striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 79:45-56.
33. Guyot MC, Palfi S, Stutzmann JM, Maziere M, Hantraye P, Brouillet E (1997b) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81:141-149.
34. Hantraye P, Riche D, Maziere M, Isacson O (1992) Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci USA 89:4187-4191.
35. Huber A, Padrun V, Deglon N, Aebischer P, Mohler H, Boison D (2001) Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci USA 98:7611-7616.
36. Jacobson KA, Von Lubitz DK, Daly JW, Fredholm BB (1996) Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol Sci 17:108-113.
37. Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR (1996) Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 16:450-461.
38. Johnson JR, Robinson BL, Ali SF, Binienda Z (2000) Dopamine toxicity following long term exposure to low doses of 3-nitropropionic acid (3-NPA) in rats. Toxicol Lett 116:113-118.
39. Knutsen LJS, Lau J, Sheardown MJ, Eskesen K, Thomsen C, Weis JU, Judge ME, Klitgaard H (1995) Anticonvulsivant actions of novel and reference adenosine agonists. In: Adenine and Adenosine Nucleotides: From Molecular Biology to Integrative Physiology (Belardinelli L, Pelleg A, eds), pp 479-488. Boston: Kluwer.
40. Lee HT, Thompson CI, Hernandez A, Lewy JL, Belloni FL (1993) Cardiac desensitization to adenosine analogues after prolonged R-PIA infusion in vivo. Am J Physiol 265:H1916-H1927.
41. 1 adenosine receptor agonist: Alterations in the quantity of GS alpha and Gi alpha are not associated with changes in their mRNAs. Mol Pharmacol 36:681-688.
42. Malenka RC, Kocsis JD (1988) Presynaptic actions of carbachol and adenosine on corticostriatal synaptic transmission studied in vitro. J Neurosci 8:3750-3756.
43. Mittoux V, Joseph JM, Conde F, Palfi S, Dautry C, Poyot T, Bloch J, Deglon N, Ouary S, Nimchinsky EA, Brouillet E, Hof PR, Peschanski M, Aebischer P, Hantraye P (2000) Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 11:1177-1187.
44. Mittoux V, Ouary S, Monville C, Lisovoski F, Poyot T, Conde F, Escartin C, Robichon R, Brouillet E, Peschanski M, Hantraye P (2002) Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J Neurosci 22:4478-4486.
45. 2+ current in hippocampal CA3 neurons. Neuron 10:327-334.
46. Nishino H, Fujimoto I, Shimano Y, Hida H, Kumazaki M, Fukuda A (1996) 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. J Chem Neuroanat 10:209-212.
47. Nishino H, Kumazaki M, Fukuda A, Fujimoto I, Shimano Y, Hida H, Sakurai T, Deshpande SB, Shimizu H, Morikawa S, Inubushi T (1997) Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: Involvement of dopamine toxicity. Neurosci Res 27:343-355.
48. Nishino H, Hida H, Kumazaki M, Shimano Y, Nakajima K, Shimizu H, Ooiwa T, Baba H (2000) The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: A hypothesis to explain its specific vulnerability. J Neurotrauma 17:251-260.
49. Ouary S, Bizat N, Altairac S, Menetrat H, Mittoux V, Conde F, Hantraye P, Brouillet E (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neuroprotection studies. Neuroscience 97:521-530.
50. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16:3019-3025.
51. Palfi S, Riche D, Brouillet E, Guyot MC, Mary V, Wahl F, Peschanski M, Stutzmann JM, Hantraye P (1997) Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. Exp Neurol 146:135-141.
52. Palfi S, Conde F, Riche D, Brouillet E, Dautry C, Mittoux V, Chibois A, Peschanski M, Hantraye P (1998) Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med 4:963-966.
53. Palmer TM, Stiles GL (1995) Adenosine receptors. Neuropharmacology 34:683-694.
54. Paxinos G, Watson C (1990) The Rat Brain in Stereotaxic Coordinates. New York: Academic.
55. Reynolds DS, Carter RJ, Morton AJ (1998) Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J Neurosci 18:10116-10127.
56. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992) Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 13:439-445.
57. Schiffmann SN, Vanderhaeghen JJ (1993) Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13:1080-1087.
58. Schiffmann SN, Desdouits F, Menu R, Greengard P, Vincent JD, Vanderhaeghen JJ, Girault JA (1998) Modulation of the voltage-gated sodium current in rat striatal neurons by DARPP-32, an inhibitor of protein phosphatase. Eur J Neurosci 10:1312-1320.
59. Schulz JB, Matthews RT, Jenkins BG, Ferrante RJ, Siwek D, Henshaw DR, Cipolloni PB, Mecocci P, Kowall NW, Rosen BR, Beal MF (1995) Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J Neurosci 15:8419-8429.
60. Schulz JB, Matthews RT, Henshaw DR, Beal MF (1996) Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience 71:1043-1048.
61. Sebastiao AM, Ribeiro JA (2000) Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci 21:341-346.
62. Sieradzan KA, Mann DM (2001) The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol 27:1-21.
63. Tarnopolsky MA, Beal MF (2001) Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 49:561-574.
64. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
65. The Huntington's Disease Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57:397-404.
66. Trussell LO, Jackson MB (1985) Adenosine-activated potassium conductance in cultured striatal neurons. Proc Natl Acad Sci USA 82:4857-4861.
67. Vis JC, Verbeek MM, De Waal RM, Ten Donkelaar HJ, Kremer HP (1999) 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum. Neuropathol Appl Neurobiol 25:513-521.
68. 1 receptor agonist and antagonist: Effect on receptor density and N-methyl-D-aspartate induced seizures in mice. Eur J Pharmacol 253:95-99.
69. 1 receptor agonist or antagonist in cerebral ischemia. Eur J Pharmacol 256:161-167.
70. 1 receptor agonist. Eur J Pharmacol 302:43-48.
71. Von Lubitz DK, Lin RC, Paul IA, Beenhakker M, Boyd M, Bischofberger N, Jacobson KA (1996b) Postischemic administration of adenosine amine congener (ADAC): Analysis of recovery in gerbils. Eur J Pharmacol 316:171-179.
72. 1 receptor agonist. Eur J Pharmacol 369:313-317.
73. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
74. White PJ, Rose'Meyer RB, Hope W (1996) Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat. Br J Pharmacol 117:305-308.
75. Williams M (1993) Purinergic drugs: Opportunities in the 1990s. Drug Res Dev 28:438-441.
76. 1 receptor mediation. Neuropharmacology 28:21-25.
77. Zetterstrom T, Fillenz M (1990) Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol 180:137-143.